Myriad Genetics' HRD Test Predicts Response to Platinum Therapy in Triple-Negative Breast Cancer
Triple-negative breast cancer describes breast tumors that lack estrogen receptor, progesterone receptor and HER2. This type of breast cancer tends to be more aggressive than other subtypes of breast cancer and has not been amenable to targeted therapies. The platinum class of drugs kill tumors by causing DNA damage inside the tumor and may be particularly effective against tumors that have lost their ability to repair DNA.
"DNA repair deficiency is believed to be a property of a significant number of triple-negative breast tumors," said Dr.
Many breast tumors are believed to be deficient in DNA repair capacity. Myriad's HRD test is designed to predict patient response to DNA damaging agents such as platinum drugs and PARP inhibitors that may be more effective against these subsets of breast cancer. With further research, the use of the HRD test may become an important tool to guide treatment decisions in all breast cancer patients.
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995,including statements relating to the ability of the HRD test to predict which primary tumors will respond to platinum-based combination therapy in patients with triple-negative breast cancer; whether the HRD test will become a important tool to guide the treatment of patients with triple-negative breast cancer and in all breast cancer patients; and the Company's strategic directives under the caption "About Myriad Genetics". These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not
limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; the risk that we may be unable to expand into new markets outside of
CONTACT: Media Contact:Source:
Stephanie Ashe Continuum Health Communications(650) 245-0425 email@example.com Investor Contact: Jim EvansChief Financial Officer (801) 584-3672 firstname.lastname@example.org
News Provided by Acquire Media